Market Size of Dacryocystitis Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 4.20 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Dacryocystitis Market Analysis
The dacryocystitis market studied is anticipated to register a CAGR of nearly 4.2%, during the forecast period.
Certain factors that are driving the market growth include a rise in the prevalence of eye infections and increasing clinical research and subsequent new product launches.
Dacryoadenitis is an inflammation of the lacrimal gland. Infections are rare and may be acute or chronic. Patients with acute dacryoadenitis suffer from a tender area of erythema and swelling in the lateral part of the upper lid. It may lead to preseptal or orbital cellulitis or may suppurate into an abscess.
As per the study titled 'Fungal infections of the eye', fungal dacryocystitis accounts for approximately 5% of all acquired dacryocystitis and around 14% of cases of congenital dacryocystitis. Women are affected more frequently with all forms of dacryocystitis than men, probably because of anatomically narrower nasolacrimal ducts. It mostly affects individuals in their 50s or 60s.
Dacryocystitis Industry Segmentation
As per the scope of the report, dacryocystitis refers to an infection of the tear sac (lacrimal sac) in the inner corner of the eye. It causes pain, redness, and swelling over the inner aspect of the lower eyelid and epiphora.
| By Indication | |
| Acute | |
| Chronic | |
| Other Indications |
| By Distribution Channel | |
| Institutional Sales | |
| Retail Sales |
| By Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Dacryocystitis Market Size Summary
The dacryocystitis market is poised for steady growth, driven by an increase in eye infections and advancements in clinical research leading to new product introductions. Dacryocystitis, characterized by inflammation of the lacrimal sac, can manifest as acute or chronic conditions, with bacterial infections being the primary cause of acute cases. The condition is more prevalent in women, likely due to anatomical differences in the nasolacrimal ducts, and predominantly affects individuals in their 50s and 60s. The market landscape is shaped by a few key players, including Aurobindo Pharma, Bess Medizintechnik GmbH, and Pfizer Inc., who hold significant market shares.
In the United States, there has been a notable increase in dacryocystitis cases, particularly among females, as evidenced by various studies. The regulatory environment and funding opportunities from organizations like the National Institute of Health have encouraged research and development in this field. The competitive nature of the market is underscored by the presence of major companies such as Glaxosmithkline PLC and Kaneka Corporation, which contribute to the ongoing innovation and availability of treatment options for dacryocystitis.
Dacryocystitis Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Rise in Prevalence of Eye Infections
-
1.2.2 Increasing Clinical Research and Subsequent New Product Launches
-
-
1.3 Market Restraints
-
1.3.1 Less Patient Awareness Regarding Various Treatment Procedures
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 By Indication
-
2.1.1 Acute
-
2.1.2 Chronic
-
2.1.3 Other Indications
-
-
2.2 By Distribution Channel
-
2.2.1 Institutional Sales
-
2.2.2 Retail Sales
-
-
2.3 By Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle-East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle-East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Dacryocystitis Market Size FAQs
What is the current Dacryocystitis Market size?
The Dacryocystitis Market is projected to register a CAGR of 4.20% during the forecast period (2024-2029)
Who are the key players in Dacryocystitis Market?
Pfizer Inc. , Aurobindo Pharma , Orex Pharma Pvt Ltd, Nosch and Mylan NV are the major companies operating in the Dacryocystitis Market.
